-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|August 21, 2024

Managing Adverse Events in Novel Friedreich’s Ataxia Therapy

A key opinion leader outlines common adverse events associated with omaveloxolone treatment in Friedreich's ataxia patients and describes strategies used to manage or minimize these adverse effects.

Episodes in this series

This series features 1 kol.

EP. 1 Friedreich Ataxia: Addressing Treatment Objectives and Comorbidities

This series features 1 kol.

EP. 2 Guidelines & FDA Approval of Novel Friedreich Ataxia Therapy

This series features 1 kol.

EP. 3 Engaging mFARS Scale to Monitor Friedreich Ataxia Progression

This series features 1 kol.

EP. 4 Managing Adverse Events in Novel Friedreich’s Ataxia Therapy

This series features 1 kol.

EP. 5 Examining Trial Data on Omaveloxolone Efficacy

This series features 1 kol.

EP. 6 Promising Therapy Approaches for Advanced Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 7 Friedreich Ataxia: Looking Forward at the Treatment Landscape

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 8 Epidemiology, Pathophysiology, and Symptomatology of Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 9 Diagnosis of Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 10 Impact of Friedreich Ataxia on Quality of Life

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 11 Clinical Utility of the Modified Friedreich Ataxia Rating Scale

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 12 Comorbidities and Complications Associated With Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 13 Challenges Associated With Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 14 Future Considerations for Friedreich Ataxia

What adverse events are typically encountered with omaveloxolone, what strategies do you employ to mitigate or address them effectively and under what circumstances should omaveloxolone be discontinued, if at all?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Ying Huang, PhD | Image: Legend Biotech

Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors

ByProduced by Mary Caffrey

June 22nd 2026

Catching DME Patients Before They Fall Off the Radar: Sunir Garg, MD

ByLaura Joszt, MA,Sunir Garg, MD

June 22nd 2026

Navigating the Human Side of Extrapulmonary Neuroendocrine Carcinoma: Patient Burden and Caregiver Support

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

June 22nd 2026

The 5-Year Horizon: Evolving Paradigms in Ischemic Stroke Management

ByMark Makhinson, PharmD, MBA,Andrew Russman, DO, FAHA, FAAN,Danison Emmerson, MD,David Z. Rose, MD

June 22nd 2026

Closing the Gap: Underrecognition and the Critical Need for Early Diagnosis in Extrapulmonary Neuroendocrine Carcinoma

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

June 22nd 2026

Trending on AJMC

Health Care Is Fixable: Workers’ Compensation Shows Employers Don’t Need to Wait for Washington

Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently

Chemo-Free Options Abound for Transplant-Ineligible MCL, Kumar Explains

FDA Issues Complete Response Letter for Cytisinicline NDA, Citing Manufacturing Deficiencies

Aficamten Outperforms Metoprolol Across All Phases of Exercise in Obstructive HCM